New Medicines, Novel Insights: Accelerating development of cell and gene therapies
Cell and gene therapies offer extraordinary hope to patients with advanced cancers and genetic diseases but pose unprecedented challenges for sponsors. In this report, Parexel experts share insights that can bring these complex treatments to market faster and more efficiently.
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Podcast
CAR-T boxed warnings: What comes next?
Mar 6, 2024
Blog
CAR-T product development: an assessment of FDA’s final guidance for industry
Feb 27, 2024
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Podcast
CAR-T boxed warnings: What comes next?
Mar 6, 2024
Blog
CAR-T product development: an assessment of FDA’s final guidance for industry
Feb 27, 2024